Precipio Signs First IV-Cell Customer Agreement
GlobeNewswire “Press Releases”
NEW HAVEN, Conn., May 10, 2022 (GLOBE NEWSWIRE) — Specialty cancer diagnostics company.(NASDAQ: PRPO), announced today that (AON) of Fort Myers, Florida, has completed its validation of Precipios proprietary IV-Cell culture media, and will adopt the product for use in its clinical cytogenetics laboratory.
The adoption of IV-Cell by industry leader AON demonstrates Precipios ability to identify a critical unmet market need, develop and bring to market a differentiated, high value solution to the customer. Previous launch of HemeScreen testing by AON in, combined with this agreement for IV-Cell serve as validation of Precipios new strategic business model as a specialty cancer diagnostics products company, and its ability to deliver multiple products to the same customer.